Avalo Therapeutics Inc (AVTX)
14.97
+0.07
(+0.47%)
USD |
NASDAQ |
Apr 15, 16:00
16.20
+1.23
(+8.22%)
Pre-Market: 08:07
Avalo Therapeutics Debt to Equity Ratio: 0.00 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | -2.025 |
| March 31, 2023 | -3.154 |
| December 31, 2022 | -1.779 |
| September 30, 2022 | -9.401 |
| June 30, 2022 | -3.144 |
| March 31, 2022 | 5.231 |
| December 31, 2021 | 1.422 |
| September 30, 2021 | 0.8058 |
| June 30, 2021 | 0.7941 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.8399 |
| June 30, 2019 | 0.8662 |
| March 31, 2019 | 0.6641 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.7895 |
| June 30, 2018 | 0.8027 |
| March 31, 2018 | 0.6255 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.1938 |
| March 31, 2017 | -3.505 |
| December 31, 2016 | 11.37 |
| September 30, 2016 | 5.436 |
| June 30, 2016 | 0.7184 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-9.401
Minimum
Sep 2022
5.231
Maximum
Mar 2022
-0.5023
Average
--
Median
Dec 2019
Debt to Equity Ratio Benchmarks
| Imunon Inc | -- |
| iBio Inc | -- |
| Kodiak Sciences Inc | -- |
| Petros Pharmaceuticals Inc | 0.6421 |
| Ocugen Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 20.99M |
| Total Liabilities (Quarterly) | 13.69M |
| Shareholders Equity (Quarterly) | 7.304M |
| Current Ratio | 1.818 |
| Net Debt Paydown Yield | 52.27% |